Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2026, with sales up 11.6% year on year to $5.20 billion. O...
Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investo...
Medical device company Boston Scientific (NYSE:BSX) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 11.6% year on year to...
Boston Scientific Corp. (NYSE:BSX) shares are in the spotlight on Tuesday after Stifel maintained a Buy rating and lowered its price target on the stock.
Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday before market hours. Here’s what you need to know. Boston Scien...
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
As of April 15, 2026, the medical technology landscape is bracing for its most significant transformation in years. Boston Scientific (NYSE:BSX) is moving steadily toward the finalization of its $14.9 billion acquisition of Penumbra, Inc. (NYSE:PEN), a deal that represents the company's largest M&A move in
In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of
The financial landscape of 2026 has been marked by a return to high-stakes deal-making and intense market fluctuations, and no institution seems more equipped to navigate this era than Bank of America (NYSE:BAC). On April 15, 2026, the banking giant reported a blockbuster first-quarter earnings beat, signaling a decisive
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing
The medical technology landscape witnessed a seismic shift on Tuesday as Avanos Medical (NYSE: AVNS) announced it has entered into a definitive agreement to be acquired by affiliates of American Industrial Partners (AIP) in an all-cash transaction valued at approximately $1.27 billion. The deal marks a significant turning point
